National Cancer Institute (NCI)s

National Cancer Institute (NCI)

472 Protocols (263 Active Accrual of new subjects, 209 Follow-up of previously enrolled subjects)

 16-C-0010:

Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

 16-C-0003:

Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies

 15-C-0195:

Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals with Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)

 15-C-0145:

Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination with Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers

 15-C-0141:

Gene Therapy Follow up Protocol for Subjects Previously Enrolled in CAR T-Cell Studies

 15-C-0093:

Phase I Trial of TURALIO (pexidartinib, PLX3397) in Children and Young Adults with Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT

 15-C-0087:

Care of the Urothelial Cancer Patient and Prospective Collection of Biospecimens from Healthy Volunteers and Urothelial Cancer Patients

 15-C-0086:

Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults and Pediatric Patients with Refractory Solid Tumors

 15-C-0067:

A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

 15-C-0028:

Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

 14-C-0161:

Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes

 14-C-0157:

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma

 14-C-0128:

Collection of Pharmacokinetic and Probe Substrate Samples from Participants with Unanticipated Response, Significant Toxicity or Concern of Future Toxicity

 14-C-0116:

A Randomized Controlled Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated with Cranial Radiation for Brain Tumors

 14-C-0105:

Tissue Procurement and Natural History Study of Patients with Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

 14-C-0104:

A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes Derived from Patients with Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen

 14-C-0079:

An Exploratory Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults with Cancer and Other Chronic Illnesses

 13-C-0202:

Tissue Procurement and Natural History Study of Patients with Malignant Mesothelioma and Other Mesothelin Expressing Cancers

 13-C-0176:

Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors

 13-C-0132:

Allogeneic Hematopoietic Stem Cell Transplant for Patients with Mutations in GATA2 or the MonoMAC Syndrome

 13-C-0131:

Inpatient Hospice with Procurement of Tissue on Expiration in Thoracic Malignancies, Bladder Cancer, Ovarian Cancer, Epithelial Cancer and Patients Treated with an Adoptive Cellular Therapy

 13-C-0119:

Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies

 12-C-0193:

Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol

 12-C-0178:

Longitudinal Assessment and Natural History Study of Children and Adults with MEN2A or MEN2B with or without Medullary Thyroid Carcinoma

 11-C-0255:

Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome

 11-C-0242:

Collection of Blood from Patients with Cancer, Other Tumors, or Tumor Predisposition Syndromes for Analysis of Genetic Differences in Drug Disposition

 11-C-0220:

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

 11-C-0190:

Collection of Tissue Blocks or Slides from Patients with Cancer

 11-C-0112:

Acquisition of Blood and Tumor Tissue Samples from Patients with Gastrointestinal Cancer

 11-C-0034:

DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

 10-C-0201:

Apheresis and CD34+ Selection of Mobilized Peripheral Blood CD34+ Cells from Patients with DOCK8 Deficiency, LAD-1, and GATA2 Deficiency

 10-C-0174:

Related and Unrelated Donor Hematopoietic Stem Cell Transplant for DOCK8 Deficiency

 10-C-0166:

A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab

 10-C-0086:

Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies

 10-C-0066:

A Study of Hairy Cell and other Leukemias with a Focus on Recombinant Immunotoxins for Cancer Treatment

 09-C-0242:

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

 09-C-0161:

Follow-Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies

 09-C-0100:

A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch

 09-C-0053:

Autologous and Related/Unrelated Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission and Research Sample Collection to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Don

 07-C-0110:

Analysis of Stored Data Collected from Individuals Administered Neurobehavioral Assessments on IRB-Approved Protocols

 07-C-0100:

Collection of Blood from Patients with Prostate Cancer

 06-C-0213:

Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)

 06-C-0014:

Prospective Evaluation of Genetic and Epigenetic Alterations in Patients with Thoracic Malignancies

 04-C-0281:

Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease

 04-C-0274:

Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic Agents

 04-C-0200:

Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence

 04-C-0165:

Data Collection, Clinical Care and Interventions in CCR, NCI

 04-C-0102:

Hematologic Malignancy Biology Study

 03-C-0277:

Cell Harvest and Preparation for Surgery Branch Treatment Protocols

 03-C-0066:

Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer

 02-C-0211:

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

 02-C-0179:

Biospecimen Acquisition from Human Subjects

 02-C-0159:

Birt-Hogg-Dub(SqrRoot)(Copyright) Syndrome: Characterization of the FLCN Disease Gene and Predisposition to Renal Cancer, Cutaneous Fibrofolliculoma and Pulmonary Cysts

 02-C-0064:

Collection of Peripheral Blood and/or Urine From Patients Undergoing Radiation Therapy

 02-C-0052:

Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study

 01-C-0129:

Eligibility Screening for the NIH Intramural Research Program Clinical Protocols

 01-C-0038:

Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer

 00-C-0078:

Collection of Blood, Fluid, Bone Marrow, Tumor, or Tissue Samples from Patients with Cancer or Normal Volunteers

 00-C-0074:

Evaluation of Late Effects and Natural History of Disease in Patients Treated with Radiotherapy

 99-C-0128:

Evaluation for NCI Surgery Branch Clinical Research Protocols

 97-C-0147:

Collection of Serum and Tissue Samples from Patients with Biopsy-Proved or Suspected Malignant Diseases

 89-C-0086:

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

 83-C-0022:

Psychological Benefits of a Normalized Camping Experience for Children with Cancer

 001951-C:

Natural History Study of Kaposi Sarcoma

 001924-C:

A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Cutaneous, Subcutaneous, Soft Tissue or Nodal Tumors

 001920-C:

A ComboMATCH Treatment Trial: FOLFOX In Combination With Binimetinib As 2nd Line Therapy For Patients With Advanced Biliary Tract Cancers With MAPK Pathway Alterations

 001859-C:

A Phase I Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

 001784-C:

Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation

 001783-C:

An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-cell Th

 001778-C:

A Randomized, Open Label, Two-Arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination with Pembrolizumab Versus Pembrolizumab in Patients with Recurrent or Metastatic Cervical Cancer

 001730-C:

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination with Immunotherapy Vaccine PRGN-2009 in Subjects with Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

 001715-C:

A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associ

 001704-C:

Randomized Phase 2 Study of Cabozantinib, Ipilimumab, and Nivolumab in Patients with Soft Tissue Sarcoma

 001696-C:

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

 001695-C:

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (anti-VISTA) as Monotherapy and in Combination with Cemiplimab in Patients with Advanced Solid Tumors

 001657-C:

Phase 1 Umbrella Trial of Erlotinib In Combination with Select Tyrosine Kinase Inhibitors In Adult Patients with Advanced Solid Tumors

 001601-C:

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

 001600-C:

Phase 2 Study Evaluating the Functional Status of the Adrenal Glands with [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism

 001599-C:

Phase I/II Trial of Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

 001583-C:

A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary

 001582-C:

Phase I/Ib Study Evaluating Safety and Efficacy of PRGN-3005 (Autologous CAR T Cells) in Advanced Stage Platinum Resistant Ovarian Cancer Patients

 001569-C:

A Phase I Study to Investigate the Safety of the Ubiquitin Activating Enzyme Inhibitor TAK-243 in Adult Solid Tumor and Lymphoma Patients

 001564-C:

A Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 alone or in Combination with PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

 001559-C:

A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

 001557-C:

Phase I/II Trial of Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination with HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants with Advanced or Metastatic Endometrial Cancer (EC)

 001554-C:

Phase I/II Trial of Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

 001545-C:

A Phase Ib/II Multicenter Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

 001537-C:

Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

 001535-C:

A Phase II Study of Sacituzumab Govitecan with or without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

 001533-C:

A Phase II Multicenter Study of Enfortumab Vedotin with or without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

 000954-C:

A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients with Advanced Mesothelin-Expressing Cancer

 000826-C:

An Open Label, Randomized, Phase 2 Study to Evaluate the Safety and Efficacy of MTL-CEBPA Administered in Combination with Sorafenib or Sorafenib Alone, in TKI Na(SqrRoot) ve Participants with Previously Treated Advanced Hepatocellular Carcinoma (HCC) an

 000696-C:

A Phase III, Multicenter, International Study with a Parallel, Randomized, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants with NF1 who have Symptomatic, Inoperable Plexiform Neurofibr

 000647-C:

An Open-label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Bintrafusp alfa (M7824) Clinical Studies

 000631-C:

Investigation of the Cognitive Aftereffects of Neurotoxicity in Children and Young Adults with Relapsed/Refractory Hematologic Malignancies who Receive CAR T-cell Therapy

 000612-C:

Phase 1 Study of NT-I7 (rhIL-7-hyFc) for the Treatment of Kaposi Sarcoma in Patients With or Without Infection with HIV

 000516-C:

Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma involving the Central Nervous System

 000484-C:

Randomized Phase II Trial of Durvalumab (D) plus Olaparib (O) and Cediranib (C: DOC) Compared to OC or DC or Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer with Prior Bevacizumab

 000478-C:

A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Bone Marrow Transplantation Followed by GVHD Prophylaxis with Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living with HIV (PLWH)

 000356-C:

A Phase I/II Trial of BMS-986253 in Myelodysplastic Syndromes

Previous 100 Protocols

Next -300 Protocols